Ono Pharmaceutical Co Ltd (OPHLY)

7.80 -0.08 (-1.02%)
Closed USD Disclaimer
7.80 -0.00 (-0.00%)

Ono Pharmaceutical Co Ltd Company Profile

Equity Type
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer’s disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson’s disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and collaboration agreement with Numab Therapeutics AG and Caris Life Sciences, Inc. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Contact Information
Osaka,541-8564 Japan
81 6 6263 5670
81 6 6263 2976
Top Executives
Yasuo Hishiyama 0 2016 Outside Audit & Supervisory Board Member
Akiko Tanabe 51 2020 Outside Audit & Supervisory Board Member
Akiko Okuno 0 2020 Independent Outside Director
Shusaku Nagae 71 2021 Independent Outside Director
Masao Nomura 72 2018 Independent Outside Director
Hironobu Tanisaka 0 2021 Outside Audit Supervisory Board Member
Katsuyoshi Nishimura 0 2011 Audit & Supervisory Board Member
Gyo Sagara 0 2008 CEO, President & Representative Director
Kiyoaki Idemitsu 0 2021 Executive Officer, Executive Director of Clinical Development & Director
Toichi Takino 0 2020 Senior Executive Officer, Executive Director of Discovery & Research and Director
Isao Ono 0 0000 Executive Officer, Director of Corporate Research & Director
Toshihiro Tsujinaka 0 2016 Senior Executive Officer, Executive Director of Corporate Strategy & Planning and Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.